BR112021011765A2 - Compostos orgânicos - Google Patents
Compostos orgânicos Download PDFInfo
- Publication number
- BR112021011765A2 BR112021011765A2 BR112021011765-2A BR112021011765A BR112021011765A2 BR 112021011765 A2 BR112021011765 A2 BR 112021011765A2 BR 112021011765 A BR112021011765 A BR 112021011765A BR 112021011765 A2 BR112021011765 A2 BR 112021011765A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- disorders
- disorder
- fact
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/007—Steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862780703P | 2018-12-17 | 2018-12-17 | |
| US62/780,703 | 2018-12-17 | ||
| PCT/US2019/066923 WO2020131918A1 (en) | 2018-12-17 | 2019-12-17 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021011765A2 true BR112021011765A2 (pt) | 2021-08-31 |
Family
ID=71100855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021011765-2A BR112021011765A2 (pt) | 2018-12-17 | 2019-12-17 | Compostos orgânicos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12325726B2 (https=) |
| EP (1) | EP3897656A4 (https=) |
| JP (1) | JP7645797B2 (https=) |
| KR (1) | KR102931436B1 (https=) |
| CN (1) | CN113226326B (https=) |
| AU (1) | AU2019406803B2 (https=) |
| BR (1) | BR112021011765A2 (https=) |
| CA (1) | CA3121636A1 (https=) |
| IL (1) | IL283960B2 (https=) |
| MX (1) | MX2021007142A (https=) |
| WO (1) | WO2020131918A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| MX2021007142A (es) | 2018-12-17 | 2021-08-11 | Intra Cellular Therapies Inc | Compuestos organicos. |
| WO2021168106A1 (en) * | 2020-02-18 | 2021-08-26 | Praxis Precision Medicines, Inc. | Deuterated neurosteroid |
| JP2023539125A (ja) * | 2020-08-20 | 2023-09-13 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| WO2023159094A2 (en) * | 2022-02-16 | 2023-08-24 | Praxis Precision Medicines, Inc. | PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| ES2296594T3 (es) | 1994-02-14 | 2008-05-01 | Euro-Celtique S.A. | Androstanos y pregnanos para la modulacion alosterica del receptor de gaba. |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| UA73736C2 (en) * | 1999-04-29 | 2005-09-15 | Euro Celtic S A | Method for alleviating or preventing insomnia and inducing anesthesia |
| WO2005105822A2 (en) | 2004-04-23 | 2005-11-10 | Euro-Celtique S.A. | 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| US20060074059A1 (en) | 2004-08-26 | 2006-04-06 | Goliber Philip A | Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one |
| ATE538797T1 (de) | 2005-06-09 | 2012-01-15 | Euro Celtique Sa | Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| CN117024501A (zh) * | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| ME03809B (me) * | 2014-10-16 | 2021-04-20 | Sage Therapeutics Inc | KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a |
| CN105985396A (zh) | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| EP4155314A1 (en) | 2015-02-20 | 2023-03-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
| MX2021007142A (es) | 2018-12-17 | 2021-08-11 | Intra Cellular Therapies Inc | Compuestos organicos. |
| JP2023539125A (ja) | 2020-08-20 | 2023-09-13 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
-
2019
- 2019-12-17 MX MX2021007142A patent/MX2021007142A/es unknown
- 2019-12-17 AU AU2019406803A patent/AU2019406803B2/en active Active
- 2019-12-17 JP JP2021534641A patent/JP7645797B2/ja active Active
- 2019-12-17 WO PCT/US2019/066923 patent/WO2020131918A1/en not_active Ceased
- 2019-12-17 EP EP19899589.6A patent/EP3897656A4/en active Pending
- 2019-12-17 CA CA3121636A patent/CA3121636A1/en active Pending
- 2019-12-17 KR KR1020217022377A patent/KR102931436B1/ko active Active
- 2019-12-17 US US17/415,667 patent/US12325726B2/en active Active
- 2019-12-17 CN CN201980083634.9A patent/CN113226326B/zh active Active
- 2019-12-17 BR BR112021011765-2A patent/BR112021011765A2/pt unknown
- 2019-12-17 IL IL283960A patent/IL283960B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3897656A4 (en) | 2022-09-21 |
| MX2021007142A (es) | 2021-08-11 |
| CN113226326B (zh) | 2024-09-20 |
| US20220073558A1 (en) | 2022-03-10 |
| WO2020131918A1 (en) | 2020-06-25 |
| CN113226326A (zh) | 2021-08-06 |
| CA3121636A1 (en) | 2020-06-25 |
| JP2022513933A (ja) | 2022-02-09 |
| IL283960B1 (en) | 2025-05-01 |
| KR20210105934A (ko) | 2021-08-27 |
| IL283960A (en) | 2021-07-29 |
| EP3897656A1 (en) | 2021-10-27 |
| IL283960B2 (en) | 2025-09-01 |
| AU2019406803A1 (en) | 2021-07-08 |
| KR102931436B1 (ko) | 2026-02-25 |
| JP7645797B2 (ja) | 2025-03-14 |
| AU2019406803B2 (en) | 2025-04-24 |
| US12325726B2 (en) | 2025-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102931436B1 (ko) | 유기 화합물 | |
| WO2022040545A1 (en) | Organic compounds | |
| EP4339189A1 (en) | Nmda receptor antagonist and use thereof | |
| NZ560368A (en) | Methods and compostions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | |
| WO2017165877A1 (en) | Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post traumatic stress disorders | |
| JP7749896B2 (ja) | 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター | |
| BR112021016457A2 (pt) | Composto, medicamento e método para tratar dor ou um distúrbio do sistema nervoso central em um paciente que precisa do mesmo | |
| JP7750582B2 (ja) | 水溶性アロプレグナノロン誘導体及びその製造方法並びに用途 | |
| JP2021519276A (ja) | Ｄ−β−ヒドロキシ酪酸の重水素化類似体およびその使用 | |
| RU2809023C2 (ru) | Органические соединения | |
| JP2026507720A (ja) | アロプレグナノロン誘導体の塩形態、多結晶形およびその調製方法と使用 | |
| WO2024044847A1 (en) | Indoline derivatives as serotonergic agents useful for the treatment of disorders related thereto | |
| HK40058207A (en) | Organic compounds | |
| CA3184192A1 (en) | Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4-b]pyridine-3-carboxyl ate compounds as cav1.2 activators | |
| HK40058207B (zh) | 有机化合物 | |
| EA041547B1 (ru) | Модуляторы рецептора гамма-аминомасляной кислоты типа a против расстройств настроения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |